-
1
-
-
8944220233
-
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe français du myélome
-
Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe français du myélome. N Engl J Med 1996; 335: 91-97.
-
(1996)
N Engl J Med
, vol.335
, pp. 91-97
-
-
Attal, M.1
Harousseau, J.L.2
Stoppa, A.M.3
Sotto, J.J.4
Fuzibet, J.G.5
Rossi, J.F.6
Casassus, P.7
Maisonneuve, H.8
Facon, T.9
Ifrah, N.10
Payen, C.11
Bataille, R.12
-
2
-
-
0028790440
-
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non- Hodgkin's lymphoma
-
Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non- Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
-
(1995)
N Engl J Med
, vol.333
, pp. 1540-1545
-
-
Philip, T.1
Guglielmi, C.2
Hagenbeek, A.3
Somers, R.4
Van Der Lelie, H.5
Bron, D.6
Sonneveld, P.7
Gisselbrecht, C.8
Cahn, J.Y.9
Harousseau, J.L.10
-
3
-
-
0027534424
-
The place of high-dose beam therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: A single-center 8-year study of 155 patients
-
Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH: The place of high-dose beam therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: a single-center 8-year study of 155 patients. Blood 1993; 81: 1137-1145.
-
(1993)
Blood
, vol.81
, pp. 1137-1145
-
-
Chopra, R.1
McMillan, A.K.2
Linch, D.C.3
Yuklea, S.4
Taghipour, G.5
Pearce, R.6
Patterson, K.G.7
Goldstone, A.H.8
-
4
-
-
0027404777
-
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
-
Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
-
(1993)
Lancet
, vol.341
, pp. 1051-1054
-
-
Linch, D.C.1
Winfield, D.2
Goldstone, A.H.3
Moir, D.4
Hancock, B.5
McMillan, A.6
Chopra, R.7
Milligan, D.8
Hudson, G.V.9
-
5
-
-
79951682257
-
The EBMT activity survey 2008 impact of team size, team density and new trends
-
in press
-
Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Apperley J, Frauendorfer K, Niederwieser D: The EBMT activity survey 2008 impact of team size, team density and new trends. Bone Marrow Transplant 2010, in press.
-
(2010)
Bone Marrow Transplant
-
-
Gratwohl, A.1
Baldomero, H.2
Schwendener, A.3
Gratwohl, M.4
Apperley, J.5
Frauendorfer, K.6
Niederwieser, D.7
-
6
-
-
33645076801
-
Early treatment-related mortality in adult autologous stem cell transplant recipients: A nation-wide survey of 1,482 transplanted patients
-
Jantunen E, Itala M, Lehtinen T, Kuittinen O, Koivunen E, Leppa S, Juvonen E, Koistinen P, Wiklund T, Nousiainen T, Remes K, Volin L: Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1,482 transplanted patients. Eur J Haematol 2006; 76: 245-250.
-
(2006)
Eur J Haematol
, vol.76
, pp. 245-250
-
-
Jantunen, E.1
Itala, M.2
Lehtinen, T.3
Kuittinen, O.4
Koivunen, E.5
Leppa, S.6
Juvonen, E.7
Koistinen, P.8
Wiklund, T.9
Nousiainen, T.10
Remes, K.11
Volin, L.12
-
7
-
-
33745989223
-
2006 update of recommendations for the use of white blood cell growth factors: An evidence- Based clinical practice guideline
-
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC: 2006 update of recommendations for the use of white blood cell growth factors: an evidence- based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3187-3205
-
-
Smith, T.J.1
Khatcheressian, J.2
Lyman, G.H.3
Ozer, H.4
Armitage, J.O.5
Balducci, L.6
Bennett, C.L.7
Cantor, S.B.8
Crawford, J.9
Cross, S.J.10
Demetri, G.11
Desch, C.E.12
Pizzo, P.A.13
Schiffer, C.A.14
Schwartzberg, L.15
Somerfield, M.R.16
Somlo, G.17
Wade, J.C.18
Wade, J.L.19
Winn, R.J.20
Wozniak, A.J.21
Wolff, A.C.22
more..
-
8
-
-
66549094588
-
Hematopoietic growth factors: ESMO recommendations for the applications
-
Crawford J, Caserta C, Roila F: Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol 2009; 20: 162-165.
-
(2009)
Ann Oncol
, vol.20
, pp. 162-165
-
-
Crawford, J.1
Caserta, C.2
Roila, F.3
-
9
-
-
33748526486
-
Morbidity and transplant-related mortality of CBV and beam preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation
-
Puig N, de la Rubia J, Remigia MJ, Jarque I, Martin G, Cupelli L, Sanz GF, Lorenzo I, Sanz J, Martinez JA, Jimenez C, Sanz MA: Morbidity and transplant-related mortality of CBV and beam preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 2006; 47: 1488-1494.
-
(2006)
Leuk Lymphoma
, vol.47
, pp. 1488-1494
-
-
Puig, N.1
De La Rubia, J.2
Remigia, M.J.3
Jarque, I.4
Martin, G.5
Cupelli, L.6
Sanz, G.F.7
Lorenzo, I.8
Sanz, J.9
Martinez, J.A.10
Jimenez, C.11
Sanz, M.A.12
-
10
-
-
55049132537
-
Highdose chemotherapy with BEAM or busulphan/ melphalan and thiotepa followed by hematopoietic cell transplantation in malignant lymphoma
-
Zaucha R, Gooley T, Holmberg L, Gopal AK, Press O, Maloney D, Bensinger WI: Highdose chemotherapy with BEAM or busulphan/ melphalan and thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma 2008; 49: 1899-1906.
-
(2008)
Leuk Lymphoma
, vol.49
, pp. 1899-1906
-
-
Zaucha, R.1
Gooley, T.2
Holmberg, L.3
Gopal, A.K.4
Press, O.5
Maloney, D.6
Bensinger, W.I.7
-
11
-
-
36549080513
-
BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non- Hodgkin's lymphoma patients: Comparative analysis of efficacy and toxicity
-
Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C: BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non- Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 2008; 87: 43-48.
-
(2008)
Ann Hematol
, vol.87
, pp. 43-48
-
-
Jo, J.C.1
Kang, B.W.2
Jang, G.3
Sym, S.J.4
Lee, S.S.5
Koo, J.E.6
Kim, J.W.7
Kim, S.8
Huh, J.9
Suh, C.10
-
12
-
-
84858864919
-
R development core team: R: A Language and Environment for Statistical Computing
-
R development core team: R: a Language and Environment for Statistical Computing. R Foundation for Statistical Computing, 2009. www.R-project.org.
-
(2009)
R Foundation for Statistical Computing
-
-
-
13
-
-
0037250159
-
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
-
Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ: A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
-
(2003)
Ann Oncol
, vol.14
, pp. 29-35
-
-
Green, M.D.1
Koelbl, H.2
Baselga, J.3
Galid, A.4
Guillem, V.5
Gascon, P.6
Siena, S.7
Lalisang, R.I.8
Samonigg, H.9
Clemens, M.R.10
Zani, V.11
Liang, B.C.12
Renwick, J.13
Piccart, M.J.14
-
14
-
-
0036467835
-
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer
-
Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727-731.
-
(2002)
J Clin Oncol
, vol.20
, pp. 727-731
-
-
Holmes, F.A.1
O'Shaughnessy, J.A.2
Vukelja, S.3
Jones, S.E.4
Shogan, J.5
Savin, M.6
Glaspy, J.7
Moore, M.8
Meza, L.9
Wiznitzer, I.10
Neumann, T.A.11
Hill, L.R.12
Liang, B.C.13
-
15
-
-
36549090123
-
Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas
-
Ballestrero A, Boy D, Gonella R, Miglino M, Clavio M, Barbero V, Nencioni A, Gobbi M, Patrone F: Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. Ann Hematol 2008; 87: 49-55.
-
(2008)
Ann Hematol
, vol.87
, pp. 49-55
-
-
Ballestrero, A.1
Boy, D.2
Gonella, R.3
Miglino, M.4
Clavio, M.5
Barbero, V.6
Nencioni, A.7
Gobbi, M.8
Patrone, F.9
-
16
-
-
77954261227
-
Pegfilgrastim versus filgrastim after highdose chemotherapy and autologous peripheral blood stem cell support
-
Castagna L, Bramanti S, Levis A, Michieli MG, Anastasia A, Mazza R, Giordano L, Sarina B, Todisco E, Gregorini AI, Santoro A: Pegfilgrastim versus filgrastim after highdose chemotherapy and autologous peripheral blood stem cell support. Ann Oncol 2010; 21: 1482-1485.
-
(2010)
Ann Oncol
, vol.21
, pp. 1482-1485
-
-
Castagna, L.1
Bramanti, S.2
Levis, A.3
Michieli, M.G.4
Anastasia, A.5
Mazza, R.6
Giordano, L.7
Sarina, B.8
Todisco, E.9
Gregorini, A.I.10
Santoro, A.11
-
17
-
-
77957938720
-
Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-sct patients
-
in press
-
Mathew S, Adel N, Rice RD, Panageas K, Duck ET, Comenzo RL, Kewalramani T, Nimer SD: Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-sct patients. Bone Marrow Transplant 2010, in press.
-
(2010)
Bone Marrow Transplant
-
-
Mathew, S.1
Adel, N.2
Rice, R.D.3
Panageas, K.4
Duck, E.T.5
Comenzo, R.L.6
Kewalramani, T.7
Nimer, S.D.8
-
18
-
-
77955888016
-
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma
-
Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaughey D, Zhan F, Boehm KA, Asmar L, Beveridge R: Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10: 186-191.
-
(2010)
Clin Lymphoma Myeloma Leuk
, vol.10
, pp. 186-191
-
-
Rifkin, R.1
Spitzer, G.2
Orloff, G.3
Mandanas, R.4
McGaughey, D.5
Zhan, F.6
Boehm, K.A.7
Asmar, L.8
Beveridge, R.9
-
19
-
-
0038663017
-
BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy
-
Jantunen E, Kuittinen T, Nousiainen T: BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma 2003; 44: 1151-1158.
-
(2003)
Leuk Lymphoma
, vol.44
, pp. 1151-1158
-
-
Jantunen, E.1
Kuittinen, T.2
Nousiainen, T.3
|